Physician profile
Sam Rae
NPI 1649277294
$3,338.31
in general payments reported to CMS, 2019-2025
23 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $182 · 2021: $430 · 2022: $482 · 2023: $540 · 2024: $802 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $599.91 | 2020-2025 | Breztri, Airsupra, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $397.41 | 2021-2025 | |
| Amgen INC. | $288.42 | 2019-2024 | Tavneos, Otezla, Repatha |
| Madrigal Pharmaceuticals | $271.87 | 2024-2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $269.44 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $232.66 | 2020-2023 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $175.63 | 2021-2025 | |
| Akebia Therapeutics INC | $130.40 | 2019-2025 | Vafseo, Auryxia |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Exact Sciences Corporation | $125.00 | 2024 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $107.53 | 2022-2025 | Acthar |
| Fresenius USA Marketing, INC. | $107.14 | 2020-2022 | |
| Travere Therapeutics, INC. | $93.24 | 2024-2025 | |
| Glaxosmithkline, LLC. | $76.63 | 2021-2023 | Benlysta |
| Ardelyx, INC. | $65.27 | 2024 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $57.60 | 2023-2025 | Jynarque |
| Daiichi Sankyo INC. | $52.33 | 2021-2022 | |
| Lilly USA, LLC | $47.57 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $41.78 | 2020-2022 | |
| Scpharmaceuticals INC. | $23.06 | 2025 | |
| Ani Pharmaceuticals, INC. | $21.17 | 2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $16.37 | 2024 | |
| Novo Nordisk INC | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Rae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.